Related coverage linked through entity extraction aliases.
May 18, 2026
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
Apr 24, 2026
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Apr 08, 2026
Enanta Pharmaceuticals will present Phase 2b data showing zelicapavir improves RSV symptom resolution by about a week and reduces hospitalization rates. The oral N-protein inhibitor also demonstrates high resistance barrier in pediatric studies. Presentations will occur at the ESCMID Global 2026 conference in Munich.
Dec 30, 2025
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
